drugset / Trial / NCT07089875

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875

Phase 3 Recruiting 500 enrolled Crystalys Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.

Timeline

Start
2025-08-01
Primary completion
2027-11-29
Completion
2027-11-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule Oral
Subject Dotinurad Small molecule 2 mg Oral
Subject Dotinurad Small molecule 4 mg Oral

Indications